

CITATION REPORT

List of articles citing

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

DOI: 10.1371/journal.pmed.0050076
PLoS Medicine, 2008, 5, e76.

Source: <https://exaly.com/paper-pdf/44608007/citation-report.pdf>

Version: 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
168	Current awareness in human psychopharmacology. 2008 , 23, 727-734		
167	Neuroleptic discontinuation during dementia care: a recent trial and its implications for practice. 2008 , 4, 528-9		3
166	False hopes, unwarranted fears: the trouble with medical news stories. <i>PLoS Medicine</i> , 2008 , 5, e118	11.6	14
165	EEG synchrony analysis for early diagnosis of Alzheimer's disease: a study with several synchrony measures and EEG data sets. 2009 , 2009, 2224-7		26
164	The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. 2009 , 8, 151-7		434
163	Primary care and dementia: 2. Long-term care at home: psychosocial interventions, information provision, carer support and case management. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 657-64	3.9	45
162	Recovery approach to the care of people with dementia: decision making and best interests concerns. 2009 , 16, 654-60		15
161	Probleemgedrag, wat doe je eraan?. 2009 , 25, 50-57		
160	Current concepts in Alzheimer's disease: a multidisciplinary review. 2009 , 24, 95-121		193
159	Management of agitation and aggression associated with Alzheimer disease. 2009 , 5, 245-55		260
158	Inappropriate Drugs in the Elderly. 2009 , 37-47		1
157	Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. 2009 , 22, 532-40		73
156	Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and neuropsychiatric symptoms in elderly patients with dementia. 2009 ,		4
155	Psychotropic medication use and cognition in institutionalized older adults with mild to moderate dementia. <i>International Psychogeriatrics</i> , 2009 , 21, 286-94	3.4	22
154	Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. <i>International Psychogeriatrics</i> , 2009 , 21, 485-93	3.4	77
153	The course of behavioral problems in elderly nursing home patients with dementia when treated with antipsychotics. <i>International Psychogeriatrics</i> , 2009 , 21, 931-40	3.4	23
152	Pharmacological treatment of dementia in people with learning disabilities. 2009 , 3, 10-19		2

151	Psychosocial interventions for reducing antipsychotic medication in care home residents. 2010 ,		
150	Het beloop van gedragsproblemen bij oudere verpleeghuispatiënten met dementie die worden behandeld met antipsychotica. 2010 ,		
149	[Therapy of psychological and behavioral symptoms in dementia]. <i>Der Nervenarzt</i> , 2010 , 81, 815-6, 818-20.5	5	
148	Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. 2010 , 212, 119-29		28
147	Aktuell. 2010 , 13, 36-41		
146	Can agitated behavior of nursing home residents with dementia be prevented with the use of standardized stimuli?. 2010 , 58, 1459-64		70
145	Violence in older people with mental illness. 2010 , 16, 339-348		11
144	The burden of psychotropic drug prescribing in people with dementia: a population database study. 2010 , 39, 637-42		81
143	Management of behavioral problems in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2010 , 22, 346-72	3.4	251
142	Management of neuropsychiatric symptoms in people with dementia. <i>CNS Drugs</i> , 2010 , 24, 729-39	6.7	85
141	Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying?. 2010 , 27, 435-49		64
140	[The use of antipsychotics in patients with dementia]. 2011 , 46, 50-3		3
139	Antipsychotic drugs. 2011 , 33, 89-123		1
138	Antipsychotics in Alzheimer's disease: A critical analysis. 2011 , 5, 38-43		3
137	Treatment of Alzheimer's disease in Brazil: II. Behavioral and psychological symptoms of dementia. 2011 , 5, 189-197		2
136	Assessment of antipsychotic prescribing in Belgian nursing homes. <i>International Psychogeriatrics</i> , 2011 , 23, 1240-8	3.4	30
135	Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. <i>International Psychogeriatrics</i> , 2011 , 23, 1623-31	3.4	27
134	Prescribing for older people in nursing homes: a review of the key issues. 2011 , 6, 45-54		16

133	A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 937-43	3.9	43
132	Management of Behavioural Problems in People with Dementia. 2011 , 4, 347-352		
131	Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 35-43	4.1	95
130	Associated factors with antipsychotic use in assisted living facilities: a cross-sectional study of 4367 residents. 2011 , 40, 368-75		17
129	Pharmacological treatment of dementia. 2012 , 25, 542-50		45
128	Knowledge of and attitudes toward nonpharmacological interventions for treatment of behavior symptoms associated with dementia: a comparison of physicians, psychologists, and nurse practitioners. 2012 , 52, 34-45		23
127	Management of agitation and aggression: controversies and possible solutions. 2012 , 68-79		
126	A long-term care center interdisciplinary education program for antipsychotic use in dementia: program update five years later. <i>International Psychogeriatrics</i> , 2012 , 24, 599-605	3.4	12
125	The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. 2012 , 20, 362-73		10
124	Antipsychotics and dementia: a time for restraint?. <i>Journal of the American Medical Directors Association</i> , 2012 , 13, 761-3	5.9	12
123	Prevalence of psychotropic medication use among German and Austrian nursing home residents: a comparison of 3 cohorts. <i>Journal of the American Medical Directors Association</i> , 2012 , 13, 187.e7-187.e13 ^{5.9}		60
122	Evidencias disponibles y criterios para la retirada de fármacos en las demencias. 2012 , 19, 547-551		
121	Relapse risk after discontinuation of risperidone in Alzheimer's disease. 2012 , 367, 1497-507		136
120	Atypical antipsychotic use in patients with dementia: managing safety concerns. 2012 , 169, 900-6		138
119	Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. 2012 , 11, 78-86		126
118	Psychosocial interventions for reducing antipsychotic medication in care home residents. <i>The Cochrane Library</i> , 2012 , 12, CD008634	5.2	35
117	Treatment of behavioral and psychological symptoms of Alzheimer's disease. 2012 , 14, 113-25		48
116	Assessment and treatment of behavior problems in dementia in nursing home residents: a comparison of the approaches of physicians, psychologists, and nurse practitioners. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 135-45	3.9	14

115	Inappropriate use of psychotropic drugs in older individuals: implications for practice. 2013 , 9, 255-264		4
114	[Developmental process of DGPPN quality indicators]. <i>Der Nervenarzt</i> , 2013 , 84, 350-65	0.5	19
113	Gene expression profile and functional analysis of Alzheimer's disease. 2013 , 28, 693-701		15
112	Antipsychotics continue to have a place in the management of difficult behavior problems in patients with dementia. <i>Journal of the American Medical Directors Association</i> , 2013 , 14, 447-9	5.9	8
111	Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. <i>The Cochrane Library</i> , 2013 , CD007726	5.2	85
110	Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. <i>International Psychogeriatrics</i> , 2013 , 25, 687-9	3.4	2
109	Discontinuation of risperidone in Alzheimer's disease. 2013 , 368, 187-8		4
108	Neuropsychiatric symptoms of dementia: consent, quality of life, and dignity. 2013 , 2013, 230134		2
107	Prescribing of antipsychotic drugs in patients with dementia: a comparison with age-matched and sex-matched non-demented controls. 2013 , 22, 1308-16		31
106	Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. <i>International Psychogeriatrics</i> , 2013 , 25, 185-203	3.4	93
105	Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring. 2014 , 2014, 843621		15
104	Management of Behavioral and Psychological Symptoms of Dementia. 2014 , 51, 303-312		4
103	Adverse drug reactions in elderly subjects hospitalized in a specialized dementia management unit. 2014 , 31, 769-76		17
102	Discontinuing inappropriate medication in nursing home residents (DIM-NHR Study): protocol of a cluster randomised controlled trial. 2014 , 4, e006082		14
101	Protocol for REducing Anti-Psychotic use in residential care-Huntington Disease (REAP-HD): a pilot cluster randomised controlled trial of a multifaceted intervention for health professionals. 2014 , 4, e006151		
100	Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. 2014 , 34, 109-23		65
99	Prescription of antipsychotics in people with dementia. 2014 , 205, 4-5		15
98	Barriers to antipsychotic discontinuation in nursing homes: an exploratory study. 2014 , 18, 346-53		26

97	The development and testing of the quality use of medications in dementia (QUM-D): a tool for quality prescribing for behavioral and psychological symptoms of dementia (BPSD). <i>International Psychogeriatrics</i> , 2015 , 27, 1313-22	3.4	2
96	Understanding of Antipsychotics in Elderly Patients with Dementia. 2015 , 14, 53		2
95	Approaches to Gradual Dose Reduction of Chronic Off-Label Antipsychotics Used for Behavioral and Psychological Symptoms of Dementia. 2015 , 30, 599-611		6
94	Medication Use Among Nursing Home Residents With Severe Dementia: Identifying Categories of Appropriateness and Elements of a Successful Intervention. <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 629.e1-17	5.9	24
93	A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 316-22	5.9	18
92	Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease. 2014 , 18,		42
91	Deprescripci3 de medicamentos. 2015 , 22, 9-33		
90	Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. 2015 , 25, 1906-13		26
89	Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related Dementias. 2015 , 63, 1757-65		11
88	Effets ind'sirables m'dicamenteux chez des sujets 3's hospitalis's dans une unit'sp'cialis'e dans la prise en charge des patients atteints de syndrome d'mentiel. 2015 , 15, 21-27		1
87	Improving the management of behaviour that challenges associated with dementia in care homes: protocol for pharmacy-health psychology intervention feasibility study. 2016 , 6, e010279		8
86	Managing Neuropsychiatric Symptoms of Neurodegenerative Diseases. 2016 , 233-253		
85	Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. 2016 , 7, 229-45		107
84	Deprescribing in older people. <i>Maturitas</i> , 2016 , 91, 115-34	5	45
83	Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: an observational study in English institutions over a 4-year period. 2016 , 6, e009882		23
82	Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trial. <i>BMJ, The</i> , 2016 , 354, i4079	5.9	36
81	The use of antipsychotics among people treated with medications for dementia in residential aged care facilities. <i>International Psychogeriatrics</i> , 2016 , 28, 977-82	3.4	11
80	The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 583-623	3.8	225

79	NEURODEM: assessment of the iatrogenic alert indicator for nursing home patients with Alzheimer's or Alzheimer-like disease. <i>Aging Clinical and Experimental Research</i> , 2016 , 28, 1015-21	4.8	1
78	Predictors of Functional Changes in Italian Nursing Home Residents: The U.L.I.S.S.E. Study. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 306-11	5.9	9
77	Dementia prevention, intervention, and care. 2017 , 390, 2673-2734		2763
76	Long-term use of antipsychotics in community-dwelling dementia patients: prevalence and profile accounting for unobservable time bias because of hospitalization. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 13-19	2.2	4
75	Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study. 2017 , 9, 34		11
74	Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. 2017 , 174, 362-369		15
73	Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. 2017 , 267, 187-198		11
72	Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy. 2017 , 7, e1250		59
71	Neuropsychiatry of dementia. 9-18		
70	Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish context. <i>BMC Psychiatry</i> , 2017 , 17, 251	4.2	3
69	The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. 2018 , 47, 430-437		23
68	Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. <i>The Cochrane Library</i> , 2018 , 3, CD007726	5.2	36
67	Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases. <i>Metabolic Brain Disease</i> , 2018 , 33, 989-1008	3.9	45
66	Deprescribing for frail older people - Learning from the case of Mrs. Hansen. <i>Research in Social and Administrative Pharmacy</i> , 2018 , 14, 612-616	2.9	5
65	Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder. <i>Mental Health Clinician</i> , 2018 , 8, 284-293	1.6	7
64	Clinical Trials on Aging Research. 2018 , 115-127		0
63	Medication review plus person-centred care: a feasibility study of a pharmacy-health psychology dual intervention to improve care for people living with dementia. <i>BMC Psychiatry</i> , 2018 , 18, 340	4.2	10
62	The OptimaMed intervention to reduce inappropriate medications in nursing home residents with severe dementia: results from a quasi-experimental feasibility pilot study. <i>BMC Geriatrics</i> , 2018 , 18, 204	4.1	11

61	General practitioners' knowledge, attitudes, and experiences of managing behavioural and psychological symptoms of dementia: A mixed-methods systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1163	3.9	23
60	Antipsychotic Deprescription for Older Adults in Long-term Care: The HALT Study. <i>Journal of the American Medical Directors Association</i> , 2018 , 19, 592-600.e7	5.9	44
59	Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 1211-1220	3.1	43
58	Pharmacological interventions for apathy in Alzheimer's disease. <i>The Cochrane Library</i> , 2018 , 5, CD012197.	7.2	37
57	Discontinuation of Long-Term Antipsychotic Drug Use for Behavioral and Psychological Symptoms in Older Adults Aged 65 Years and Older With Dementia. <i>Journal of the American Medical Directors Association</i> , 2018 , 19, 1009-1014	5.9	5
56	Psychotropic drug prescribing in residential aged care homes. <i>Medical Journal of Australia</i> , 2018 , 208, 389-390	4	1
55	Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. <i>PLoS Medicine</i> , 2018 , 15, e1002500	11.6	89
54	Why deprescribing antipsychotics in older people with dementia in long-term care is not always successful: Insights from the HALT study. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 1572-1581	3.9	10
53	Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019 , 165, 5-32	3	31
52	24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 21-31	4.3	7
51	Adaptation of a deprescription intervention to the medication management of older people living in long-term care facilities. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 1091-1098	4.1	3
50	Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia. <i>British Journal of Pharmacology</i> , 2019 , 176, 3413-3434	8.6	6
49	Reducing inappropriate prescribing for older adults with advanced frailty: A review based on a survey of practice in four countries. <i>Maturitas</i> , 2019 , 126, 1-10	5	4
48	Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA. <i>Drugs in R and D</i> , 2019 , 19, 93-115	3.4	21
47	Health Outcomes of Deprescribing Interventions Among Older Residents in Nursing Homes: A Systematic Review and Meta-analysis. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 362-372.e11	5.9	62
46	Improving the quality of life of care home residents with dementia: Cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia. <i>Alzheimer's and Dementia</i> , 2019 , 15, 282-291	1.2	13
45	Quantifying placebo responses in clinical evaluation of neuropsychiatric symptoms in Alzheimer's disease. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 497-509	2.8	5
44	Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020 , 33, 175-184	3.8	16

43	Preparing care home staff to manage challenging behaviours among residents living with dementia: A mixed-methods evaluation.. <i>Health Psychology Open</i> , 2020 , 7, 2055102920933065	1.9	0
42	Drug Burden Index and Cognitive and Physical Function in Aged Care Residents: A Longitudinal Study. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 1086-1092.e1	5.9	2
41	A European Academy of Neurology guideline on medical management issues in dementia. <i>European Journal of Neurology</i> , 2020 , 27, 1805-1820	6	23
40	An Interprofessional Workshop to Enhance De-prescribing Practices Among Health Care Providers. <i>Journal of Continuing Education in the Health Professions</i> , 2020 , 40, 49-57	2.1	4
39	Prescribing psychotropic medications in residential aged care facilities. <i>Medical Journal of Australia</i> , 2020 , 212, 304-305	4	1
38	MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention. <i>BMC Health Services Research</i> , 2020 , 20, 157	2.9	4
37	Evidence for the impact of interventions and medicines reconciliation on problematic polypharmacy in the UK: A rapid review of systematic reviews. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 42-75	3.8	1
36	Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021 , 8, 520-533	3.8	1
35	Polypharmacy Management in Older Patients. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 242-256	6.4	13
34	Atypical antipsychotics in the treatment of psychotic symptoms in Alzheimer's disease: a systematic review. <i>International Clinical Psychopharmacology</i> , 2021 , 36, 169-180	2.2	2
33	Medications use among women with dementia: a cohort study. <i>Aging Clinical and Experimental Research</i> , 2021 , 1	4.8	
32	Cost-utility analysis of a consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients. <i>BMC Geriatrics</i> , 2021 , 21, 327	4.1	0
31	PRN Medicines Management for Older People with Long-Term Mental Health Disorders in Home Care. <i>Risk Management and Healthcare Policy</i> , 2021 , 14, 2841-2849	2.8	2
30	Relevance of 5-HT Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy. <i>CNS Drugs</i> , 2021 , 35, 727-741	6.7	5
29	The value of deprescribing in older adults with dementia: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1367-1382	3.8	2
28	Encyclopedia of Clinical Neuropsychology. 2011 , 452-453		3
27	S3-Leitlinie »Demenzen« – Kurzversion. 2010 , 73-123		1
26	Certified Nursing Assistants Want to Use External Memory Aids for Residents With Dementia: Survey Results Within an Implementation Science Framework. <i>American Journal of Speech-Language Pathology</i> , 2019 , 28, 591-598	3.1	4

25	Antipsychotics for people with dementia. <i>BMJ, The</i> , 2008 , 337, a602	5.9	15
24	Psychiatric Aspects of Dementia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016 , 22, 600-14	3	11
23	Differential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011. <i>PLoS ONE</i> , 2013 , 8, e68976	3.7	35
22	Using an Electronic Decision Support Tool to Reduce Inappropriate Polypharmacy and Optimize Medicines: Rationale and Methods. <i>JMIR Research Protocols</i> , 2016 , 5, e105	2	6
21	All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 1340-7	4.6	78
20	Antipsychotic use in elderly patients with dementia: Efficacy and safety concerns. <i>Mental Health Clinician</i> , 2014 , 4, 170-176	1.6	1
19	Implementation science in the nursing home. <i>International Psychogeriatrics</i> , 2021 , 33, 865-866	3.4	
18	Differences in Dementia Care Between Swedish-Born and Foreign-Born from Countries with Different Country Level Socioeconomic Position: A Nationwide Register-Based Study. <i>Journal of Alzheimer's Disease</i> , 2021 , 84, 1363-1371	4.3	0
17	Behavioural Management in Alzheimer's Disease & Pharmacology. 2010 , 312-323		
16	De-escalation of antipsychotic medications in an elderly patient with Alzheimer's dementia residing in an assisted living facility. <i>Mental Health Clinician</i> , 2012 , 2, 115-118	1.6	
15	Therapie Psychischer Erkrankungen - Pages 1-91. 2014 , 1-91		
14	Clinical Trials. 2015 , 85-93		
13	Dementia Palliative Care. 2016 , 247-260		1
12	Encyclopedia of Clinical Neuropsychology. 2017 , 1-2		
11	Encyclopedia of Clinical Neuropsychology. 2018 , 638-640		
10	[Evidence database for deprescribing of antipsychotic drugs in elderly and senile patients]. <i>Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova</i> , 2019 , 119, 162-172	0.4	0
9	Impact of an interdisciplinary intervention for distress behaviors in dementia on psychotropic drug use in Veterans Health Administration Community Living Centers: STAR-VA impact on psychotropic drug utilization. <i>Geriatric Nursing</i> , 2021 , 42, 1533-1540	2.1	0
8	Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. <i>Canadian Family Physician</i> , 2018 , 64, 17-27	0.9	65

7	. <i>Canadian Family Physician</i> , 2018 , 64, e1-e12	0.9	0
6	Deprescribing: What is the gold standard? Themes that characterized the discussions at the first Danish symposium on evidence-based deprescribing.. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022 , 5, 100102		
5	Relapse in Dementia-related Psychosis and Clinical Decisions.. <i>Alzheimer Disease and Associated Disorders</i> , 2022 ,	2.5	
4	Health Impacts and Characteristics of Deprescribing Interventions in Older Adults: Protocol for a Systematic Review and Meta-analysis. <i>JMIR Research Protocols</i> , 2021 , 10, e25200	2	1
3	âDeprescribingâ von Antipsychotika bei Demenz. <i>Der Nervenarzt</i> ,	0.5	0
2	The OptimaMed intervention to reduce medication burden in nursing home residents with severe dementia: Results from a pragmatic, controlled study.		0
1	Impact of the Covid-19 pandemic on neuropsychiatric symptoms and antipsychotic prescribing for people with dementia in nursing home settings.		0